Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Recurrent Breast Cancer
Interventions: DRUG: Eribulin|DRUG: Balixafortide
Sponsor: Spexis AG